<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Despite advances in therapy for the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, many patients die of <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">hepatic disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Current immunotherapeutic strategies are likely limited by inhibitory signals from the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To successfully eliminate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> deposits within an organ, an appropriate immunologic milieu to amplify antitumor responses must be developed </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We used a murine model utilizing the CT26 <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cell line to analyze primary and memory <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific T-cell responses induced by an attenuated actin A and internalin B deleted immunodominant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated antigen expressing strain of Listeria monocytogenes for the treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Treatment of mice bearing established <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> with this L. monocytogenes strain led to the generation of a strong initial <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific cytotoxic CD8(+) T-cell response that successfully treated 90% of animals </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> antigen-specific central and effector memory T cells were also generated and protected against <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> rechallenge </plain></SENT>
<SENT sid="6" pm="."><plain>These cell populations, when measured before and after <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> rechallenge, showed a marked expansion of antigen-specific effector CD8(+) effector memory T cells </plain></SENT>
<SENT sid="7" pm="."><plain>This strain of L. monocytogenes was able to down-modulate the expression of the immune checkpoint molecule, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1, within the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment but had variable effects on CTLA-4 expression </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This L. monocytogenes strain generated a highly effective antitumor T-cell response, providing a basis for the development of this vaccine platform in patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
</text></document>